Zanzalintinib for advanced liver cancer after prior treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that cannot be cured with surgery or other local treatments.
- Your cancer has grown during or after one or two prior treatments (excluding cabozantinib), or you had side effects from those treatments.
- Your liver function is fairly good (Child-Pugh class A or B7/B8) and you have no serious liver-related complications like recent confusion from liver disease or fluid buildup needing drainage.
- You are able to take oral medications, are at least 18 years old, and have a good ability to do daily activities (ECOG 0 or 1).
- Your blood counts and organ function meet specific lab thresholds (like enough neutrophils, hemoglobin, platelets, and healthy kidneys and liver).
- You agree to use effective contraception during the study and for a period after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy pill (XL092, also called zanzalintinib) for people with certain advanced sarcomas that have not responded to other treatments. The goal is to see if the drug shrinks tumors or slows their growth.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has grown after at least one prior treatment. The drug may help shrink tumors or slow their growth.
This trial tests two new drugs together for people with advanced liver cancer that has not responded to other treatments or who cannot take standard immunotherapies. The combination aims to target specific genetic changes in the tumor to slow or stop its growth.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.